PTAB challenges

Proceedings overview

The USPTO Open Data Portal (ODP) API currently reports no AIA trial proceedings on file for US Patent 7,323,982. Despite this, web search reveals that an ex parte reexamination, not an AIA trial, was requested for this patent by Unified Patents in July 2025 and granted in August 2025. This means that while there are no inter partes reviews (IPRs), post-grant reviews (PGRs), or covered business method (CBM) reviews, the patent's claims are undergoing reexamination by the USPTO.

There are no PTAB (AIA trial) proceedings on file for US Patent 7,323,982.

Strategic summary

As there are no AIA trial proceedings (IPR, PGR, CBM) on file for US Patent 7,323,982, all claims of the patent remain UNTESTED by these specific PTAB mechanisms. Therefore, there are no claims currently canceled or sustained through IPR, PGR, or CBM. The estoppel provisions of § 315(e)(2) are not applicable as no such proceedings have concluded.

However, it is crucial to note that an ex parte reexamination of the patent was requested by Unified Patents in July 2025 and subsequently granted by the Central Reexamination Unit (CRU) in August 2025. This reexamination found "substantial new questions of patentability" for the challenged claims. This indicates that the validity of the patent's claims is currently under scrutiny by the USPTO, although through a different administrative process than an AIA trial. The outcome of this reexamination could lead to the cancellation of claims, similar to an IPR, but the process and estoppel effects are different.

The patent owner, Wirelesswerx IP LLC, has been aggressive in asserting this patent in district court litigation, as evidenced by the numerous cases filed across various U.S. District Courts in 2024 and 2025. The initiation of an ex parte reexamination by Unified Patents suggests a defensive aggregation effort, aiming to challenge the patent's validity without direct involvement in an IPR.

Recommended next steps

• Monitor the ex parte reexamination: A defendant facing assertion of US7323982 should closely monitor the ongoing ex parte reexamination initiated by Unified Patents. The reexamination could lead to claim cancellation, which would be highly beneficial for a defendant. The details of this reexamination (e.g., reexamination number) would need to be obtained to track its progress.
• Evaluate reexamination outcomes: If the reexamination results in the cancellation of claims, these canceled claims cannot be asserted in litigation. This would significantly narrow the scope of the patent and potentially render existing infringement theories moot.
• Consider filing an IPR (if applicable): Given the patent's expiration on December 29, 2025, the window for filing an IPR would typically be closed for claims that have been issued for more than nine months. However, if the reexamination uncovers new prior art or legal issues, or if the asserted claims were amended during reexamination, it might open avenues for new challenges, though the patent's expired status means future infringement cannot be claimed.
• Absence of PTAB activity is a signal: The lack of IPR, PGR, or CBM proceedings for a patent that has been extensively litigated often indicates that prior art challenges through these avenues may have been deemed difficult, or that the patent has survived initial assessments for such challenges. However, the ex parte reexamination indicates that validity challenges are indeed being pursued.
• Review district court filings: Analyze the district court complaints and any preliminary invalidity contentions in the active cases to understand the specific claims being asserted and the invalidity arguments already being made by other defendants. This can inform any potential strategies for a new defendant.